Ocugen’s Bold Gene Therapy Leap | Business and Finance News

Ocugen’s Q2 earnings reveal a powerhouse pipeline: FDA-cleared Phase 3 trials for OCU410 in geographic atrophy with RMAT status, plus a Middle East/North Africa deal for OCU400. A $130M convertible note extends cash runway to 2028, funding three late-stage programs targeting retinitis pigmentosa, Stargardt disease, and geographic atrophy — affecting 3 million people. Their breakthrough platform delivers one injection to modulate master regulators, potentially treating multiple gene networks without serious adverse events in over 325 patients. With BLA filings targeted for 2028 and catalysts lined up for 2027, Ocugen is poised to redefine gene therapy for blindness — and build a commercial future on durable, single-dose cures. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/d8771dd22b5671b6